Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004259 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
A Phase 3 study of Brain and Central Nervous System Tumors, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 230
- Enrollment target
- 20
- Study locations
NCT00004259 is a Phase 3 study of Brain and Central Nervous System Tumors that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 230 participants, above the 179-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT00004259, a Phase 3 study of Brain and Central Nervous System Tumors, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 230 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as temozolomide, carmustine, and lomustine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: This randomized phase III trial is studying radiation therapy and temozolomide to see how well they work compared to radiation therapy and carmustine or lomustine in treating patients with anaplastic astrocytoma or mixed gliomas.
Conditions Studied
Interventions
- RADIATION radiation therapy
- DRUG CCNU
- DRUG BCNU 80mg/m2
- DRUG TMZ 200mg/m2
- DRUG BCNU 150mg/m2
Study Locations (20)
Florida
- Lynn Regional Cancer Center at Boca Raton Community Hospital - Main Center - Boca Raton
- University of Florida Shands Cancer Center - Gainesville
- Baptist Cancer Institute - Jacksonville - Jacksonville
- Florida Oncology Associates at Southside Cancer Center - Jacksonville
- Baptist Medical Center South - Jacksonville
- Integrated Community Oncology Network - Jacksonville Beach
- Florida Oncology Associates - Orange Park
- Florida Cancer Center - Palatka - Palatka
- Flagler Cancer Center - Saint Augustine
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida - Tampa
Illinois
- St. Joseph Medical Center - Bloomington
- Graham Hospital - Canton
- Memorial Hospital - Carthage
- Eureka Community Hospital - Eureka
California
- Enloe Cancer Center at Enloe Medical Center - Chico
- North Bay Cancer Center - Fairfield
- Solano Radiation Oncology Center - Vacaville
Alabama
- Mobile Infirmary Medical Center - Mobile
Arizona
- Arizona Oncology Services Foundation - Phoenix
Georgia
- John B. Amos Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2000-06 |
| Est. Completion | 2018-05-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004259
The ClinicalTrials.gov registry entry for NCT00004259 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 179-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (28% higher). The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 5 interventions - of which radiation therapy is the first listed.
NCT00004259 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, Illinois, California.
Frequently Asked Questions
What is clinical trial NCT00004259 about?
NCT00004259 is a clinical study titled "Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as temozolomide, carmustine, and lomustine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor...
What is the current status of trial NCT00004259?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 230 participants. The study started on 2000-06. Estimated completion is 2018-05-14.
What conditions does trial NCT00004259 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00004259?
The interventions under investigation include: radiation therapy (RADIATION), CCNU (DRUG), BCNU 80mg/m2 (DRUG), TMZ 200mg/m2 (DRUG), BCNU 150mg/m2 (DRUG).
Who is sponsoring clinical trial NCT00004259?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004259 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
ACTIVE NOT RECRUITING · Phase 3
-
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme
COMPLETED · Phase 3
-
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
COMPLETED · Phase 3
-
Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.